HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.
A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.
A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...
The U.S. FDA has recommended new labeling changes for testosterone products based on clinical and post-market studies related to blood pressure and cardiovascular effects.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.